Menu Search
Equities

Ligand Pharmaceuticals Inc

LGND:NMQ

Ligand Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)105.01
  • Today's Change1.33 / 1.28%
  • Shares traded86.22k
  • 1 Year change+65.89%
  • Beta1.0456
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy0
Outperform6
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 6 analysts offering 12 month price targets for Ligand Pharmaceuticals Inc have a median target of 120.00, with a high estimate of 144.00 and a low estimate of 110.00. The median estimate represents a 14.27% increase from the last price of 105.01.
High37.1%144.00
Med14.3%120.00
Low4.8%110.00

Earnings history & estimates in USD

On Aug 06, 2024, Ligand Pharmaceuticals Inc reported 2nd quarter 2024 earnings of 1.40 per share. This result exceeded the 1.06 consensus of the 5 analysts covering the company and under-performed last year's 2nd quarter results by 1.41%.
The next earnings announcement is expected on Nov 06, 2024.
Average growth rate+2.69%
Ligand Pharmaceuticals Inc reported annual 2023 earnings of 6.09 per share on Feb 27, 2024.
Average growth rate+22.52%
More ▼

Revenue history & estimates in USD

Ligand Pharmaceuticals Incorporated had 2nd quarter 2024 revenues of 41.53m. This bettered the 32.87m consensus of the 6 analysts covering the company. This was 5.57% below the prior year's 2nd quarter results.
Average growth rate+13.62%
Ligand Pharmaceuticals Incorporated had revenues for the full year 2023 of 131.31m. This was 33.09% below the prior year's results.
Average growth rate+10.34%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.